Ion channel News

Ion channel News http://ionchannelcentral.wordpress.com News on Ion Channel Modulators for the Pharma industry Fri, 24 Oct 2008 18:00:57 +0000 en hourly 1 http://wordpress.com/ http://s2.wp.com/i/buttonw-com.png Ion channel News http://ionchannelcentral.wordpress.com Eisai publish series of BK Channel-Opening Agents http://ionchannelcentral.wordpress.com/2008/10/24/eisai-publish-series-of-bk-channel-opening-agents/ http://ionchannelcentral.wordpress.com/2008/10/24/eisai-publish-series-of-bk-channel-opening-agents/#comments Fri, 24 Oct 2008 18:00:57 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=128 ]]> Eisai have published a series of Oxime and Oxime Ether 12,14-Dichlorodehydroabietic Acid derivative BK Channel-Opening Agents

]]> http://ionchannelcentral.wordpress.com/2008/10/24/eisai-publish-series-of-bk-channel-opening-agents/feed/ 0 crimsoncanary Sucampos Lubiprostone safe and effective in Chronic Idiopathic Constipation http://ionchannelcentral.wordpress.com/2008/10/24/sucampos-lubiprostone-safe-and-effective-in-chronic-idiopathic-constipation/ http://ionchannelcentral.wordpress.com/2008/10/24/sucampos-lubiprostone-safe-and-effective-in-chronic-idiopathic-constipation/#comments Fri, 24 Oct 2008 17:12:57 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=126 ]]> Sucampo have announced results from 3 open-labeled, long-term clinical trials of lubiprostone (AMITIZA) in patients with Chronic Idiopathic Constipation (CIC).

]]> http://ionchannelcentral.wordpress.com/2008/10/24/sucampos-lubiprostone-safe-and-effective-in-chronic-idiopathic-constipation/feed/ 0 crimsoncanary Glenmark/Lilly suspend trials with TRPV1 antagonist GRC 6211 in OA http://ionchannelcentral.wordpress.com/2008/10/24/glenmarklilly-suspend-trials-with-trpv1-antagonist-grc-6211-in-oa/ http://ionchannelcentral.wordpress.com/2008/10/24/glenmarklilly-suspend-trials-with-trpv1-antagonist-grc-6211-in-oa/#comments Fri, 24 Oct 2008 16:50:18 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=124 ]]> Glenmark and Lilly have announced they have suspended further clinical development for TRPV1 antagonist GRC 6211 in Osteoarthritis pain.

]]> http://ionchannelcentral.wordpress.com/2008/10/24/glenmarklilly-suspend-trials-with-trpv1-antagonist-grc-6211-in-oa/feed/ 0 crimsoncanary NeurogesX Submit NDA for NGX-4010 for Treatment of Postherpetic Neuralgia (PHN) http://ionchannelcentral.wordpress.com/2008/10/24/neurogesx-submit-nda-for-ngx-4010-for-treatment-of-postherpetic-neuralgia-phn/ http://ionchannelcentral.wordpress.com/2008/10/24/neurogesx-submit-nda-for-ngx-4010-for-treatment-of-postherpetic-neuralgia-phn/#comments Fri, 24 Oct 2008 16:49:10 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=122 ]]> NeurogesX have submitted a new drug application (NDA) with the U.S. FDAS for NGX-4010 Dermal Capsaicin Patch for the management of pain due to postherpetic neuralgia (PHN).

]]> http://ionchannelcentral.wordpress.com/2008/10/24/neurogesx-submit-nda-for-ngx-4010-for-treatment-of-postherpetic-neuralgia-phn/feed/ 0 crimsoncanary Valeant and GSK complete wordlwide collaboration for retigabine http://ionchannelcentral.wordpress.com/2008/10/20/valeant-and-gsk-complete-wordlwide-collaboration-for-retigabine/ http://ionchannelcentral.wordpress.com/2008/10/20/valeant-and-gsk-complete-wordlwide-collaboration-for-retigabine/#comments Mon, 20 Oct 2008 14:00:31 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=119 ]]> Valeant has closed on its exclusive worldwide collaboration agreement with GlaxoSmithKline (GSK) for neuronal potassium channel opener retigabine, for the treatment of adult epilepsy patients with refractory partial onset seizures. Valeant received an upfront payment of $125 million from GSK.

]]> http://ionchannelcentral.wordpress.com/2008/10/20/valeant-and-gsk-complete-wordlwide-collaboration-for-retigabine/feed/ 0 crimsoncanary Icagen being Phase II trial of Senicapoc in Allergic Asthma http://ionchannelcentral.wordpress.com/2008/10/14/icagen-being-phase-ii-trial-of-senicapoc-in-allergic-asthma/ http://ionchannelcentral.wordpress.com/2008/10/14/icagen-being-phase-ii-trial-of-senicapoc-in-allergic-asthma/#comments Tue, 14 Oct 2008 17:52:52 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=117 ]]> Icagen have initiated a Phase II clinical trial of KCa3.1 potassium ion channel blocker senicapoc in patients with allergic asthma.

]]> http://ionchannelcentral.wordpress.com/2008/10/14/icagen-being-phase-ii-trial-of-senicapoc-in-allergic-asthma/feed/ 0 crimsoncanary Sciele/Plethora initiate Phase III trials of PSD502 for Premature Ejaculation http://ionchannelcentral.wordpress.com/2008/10/01/scieleplethora-initiate-phase-iii-trials-of-psd502-for-premature-ejaculation/ http://ionchannelcentral.wordpress.com/2008/10/01/scieleplethora-initiate-phase-iii-trials-of-psd502-for-premature-ejaculation/#comments Wed, 01 Oct 2008 14:42:10 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=112 ]]> Sciele Pharma and Plethora Solutions have initiated a Phase III Trials for PSD502 for Premature Ejaculation. PSD502 is a proprietary formulation of two marketed drugs – lidocaine and prilocaine – dispensed by a metered dose aerosol.

]]> http://ionchannelcentral.wordpress.com/2008/10/01/scieleplethora-initiate-phase-iii-trials-of-psd502-for-premature-ejaculation/feed/ 0 crimsoncanary Columbia Laboratories report Phase II results of lidocaine in vaginal dryness http://ionchannelcentral.wordpress.com/2008/09/30/columbia-laboratories-report-phase-ii-results-of-lidocaine-in-vaginal-dryness/ http://ionchannelcentral.wordpress.com/2008/09/30/columbia-laboratories-report-phase-ii-results-of-lidocaine-in-vaginal-dryness/#comments Tue, 30 Sep 2008 13:50:00 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=109 ]]> Columbia Laboratories’ vaginally-administered lidocaine has demonstrated efficacy in the treatment of vaginal dryness through dysmenorrhea. although did not meet primary endpoint

]]> http://ionchannelcentral.wordpress.com/2008/09/30/columbia-laboratories-report-phase-ii-results-of-lidocaine-in-vaginal-dryness/feed/ 0 crimsoncanary Merck publish series of T-Type Calcium Channel blockers http://ionchannelcentral.wordpress.com/2008/09/26/merck-publish-series-of-t-type-calcium-channel-blockers/ http://ionchannelcentral.wordpress.com/2008/09/26/merck-publish-series-of-t-type-calcium-channel-blockers/#comments Fri, 26 Sep 2008 14:51:46 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=107 ]]> Merck have published a series of T-Type Calcium Channel blockers

]]> http://ionchannelcentral.wordpress.com/2008/09/26/merck-publish-series-of-t-type-calcium-channel-blockers/feed/ 0 crimsoncanary Senicapoc blocks KCa3.1 currents in mast cells http://ionchannelcentral.wordpress.com/2008/09/23/senicapoc-blocks-kca31-currents-in-mast-cells/ http://ionchannelcentral.wordpress.com/2008/09/23/senicapoc-blocks-kca31-currents-in-mast-cells/#comments Tue, 23 Sep 2008 14:24:13 +0000 crimsoncanary http://ionchannelcentral.wordpress.com/?p=105 ]]> Data presented at the 15th International Inflammation Research Association Conference show Icagen’s KCa3.1 potassium ion channel inhibitor senicapoc to potently block KCa3.1 potassium currents in isolated human lung mast cells and reduce the migration of these cells when exposed to an inflammatory stimulus.

]]> http://ionchannelcentral.wordpress.com/2008/09/23/senicapoc-blocks-kca31-currents-in-mast-cells/feed/ 0 crimsoncanary